THE GOLD STANDARD IN THIRD-PARTY CERTIFICATION AND TESTING : +1-800-920-6605, info@bscg.org
Feb 23, 2026
CJC-1295 is a growth hormone–releasing peptide that has transitioned from research settings into online marketplaces, prompting regulatory considerations for athletes, military personnel, and supplement manufacturers. Global anti-doping authorities and military drug testing programs include CJC-1295 among prohibited substances. This article defines CJC-1295, details its mechanism, and outlines its regulatory status in sports and the military.
CJC-1295 is a synthetic analogue of growth hormone–releasing hormone (GHRH) developed by ConjuChem Biotechnologies in the early 2000s. Composed of 30 amino acids, CJC-1295 stimulates the pituitary gland to increase growth hormone production. The World Anti-Doping Agency (WADA) classifies CJC-1295 under Category S2 on the WADA Prohibited List as a peptide hormone and growth factor releasing agent. This category includes substances that facilitate muscle repair, recovery, and oxygen transport.
CJC-1295 is available in two main forms. The variant with Drug Affinity Complex (DAC) has a 6 to 8-day half-life that enables sustained hormone release. The form without DAC, also known as Mod GRF 1-29, has a shorter half-life and supports a pulsatile release pattern that replicates the natural secretion of growth hormone.
CJC-1295 was initially developed for potential therapeutic application in growth hormone deficiencies. It is not FDA-approved for any medical use and retains the status of a developmental drug. Although lacking regulatory approval, it is accessible via online sellers and compounding pharmacies. These products are frequently marketed as "research chemicals" or included in performance or recovery product formulations.
The peptide market also encompasses AOD 9604, BPC 157, MOTS-c, ipamorelin, tesamorelin, and sermorelin. Numerous peptides are misrepresented as dietary supplements or sold as research chemicals. These are developmental drug substances and not legally available for human consumption. For example, combinations of GHRP-6 and CJC-1295 have been listed on Amazon India in consumer-facing peptide product blends, illustrating these substances’ reach through major retailers.
CJC-1295 binds to GHRH receptors in the pituitary gland to increase growth hormone secretion. Research indicates that CJC-1295 can elevate growth hormone levels between 200 and 1,000%, with effects lasting for up to six days post-administration.
The pituitary secretes growth hormone as physiologically required for recovery and adaptation following physical exertion. Growth hormone and insulin interact to promote insulin-like growth factors (IGF), which support tissue repair after exercise and stress. Increased IGF production enhances adaptation and recovery potential.
WADA classifies CJC-1295 in Category S2, reflecting its ability to influence muscle repair and adaptation via growth factor pathways. This regulatory stance in sport drug testing is based on the peptide’s biological activity and potential impact on athlete physiology.
CJC-1295 is explicitly listed as a prohibited substance on the WADA Prohibited List (Section S2.2.4) as a growth hormone releasing factor. The prohibition applies at all times, both during and outside of competition. The WADA Prohibited List is the definitive reference for banned substances in sport and forms the basis for mandatory compliance among all Code Signatories.
Organizations such as professional sports leagues, collegiate programs, and bodies overseeing military and first-responder drug testing typically adopt or adapt the WADA Prohibited List for their banned substance policies. The U.S. Department of Defense includes testing for substances covered in WADA categories S0-S5. The S2 classification applies irrespective of dose or administration route, and under the principle of strict liability, athletes are responsible for substances detected in their sample.
Sport drug testing programs worldwide use the WADA Prohibited List as their regulatory framework. Under S2, CJC-1295 is grouped with peptides such as CJC-1293, sermorelin, tesamorelin, anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin, and tabimorelin. These peptides are distributed as unapproved and unauthorized research chemicals and are categorized as performance-enhancing agents.
WADA-accredited laboratories have developed analytical methods for detecting CJC-1295 and related peptides. WADA guidance for Growth Hormone Releasing Factors requires detection capacity for these substances. Analytical platforms can identify these compounds in urine at picogram-per-milliliter concentrations, permitting violation findings even at exposure levels below physiological relevance.
Despite technical capabilities, significant detection gaps for certain peptides remain. Until analytical coverage becomes comprehensive, some peptides may not be routinely detected in anti-doping controls, despite their appearance on prohibited substance lists. However, retrospective testing allows for retesting of samples over a 10 year period allowing technology to catch up with anyone currently trying to evade detection.
The Department of Defense includes CJC-1295 on its list of prohibited ingredients. Service members have faced career-ending outcomes for inadvertent possession of supplements containing CJC-1295 and related substances. Policy applies strict liability following a positive test result, regardless of an individual's intent or product label transparency.
Military policy holds personnel accountable for positive test results stemming from both intentional and inadvertent ingestion, including situations involving supplement contamination. Consequences include administrative action and legal proceedings.
Military drug testing panels routinely expand in scope to address emerging substances, with policies overlapping established anti-doping standards. Detection for performance-enhancing agents and relevant masking compounds occurs using standards similar to those in professional and Olympic sports testing. The military 26 panel test meanwhile focuses on a traditional list of drugs of abuse and street drugs.
Dietary supplements pose an established risk for anti-doping rule violations. Analyses have determined that up to 25% of supplements contain banned substances with some sources suggesting that up to 60% of positive drug tests attributed to supplement contamination. The risk is heightened by unapproved peptides and WADA-prohibited agents such as those classified in S2.
Most peptide substances are sold in environments with no manufacturing or quality control protocols to verify identity or detect contaminants. CJC-1295 is a synthetic peptide and does not meet the legal requirements for incorporation into food or dietary supplements. Products containing such peptides are not likely compliant with FDA regulations and may result in regulatory enforcement.
The FDA has noted safety issues with CJC-1295. According to FDA advisory committee documents from December 2024, nonclinical studies reported findings of reduced food and water intake, softer stools, decreased activity, vomiting, reduced hemoglobin, increased cholesterol, injection site inflammation and necrosis, and DNA damage in pituitary cells.
Third-party certification programs that evaluate products for WADA-listed drugs use scientific protocols to verify composition. The U.S. Department of Defense Operation Supplement Safety (OPSS) recommends third-party certification programs, such as BSCG, to mitigate risk for military personnel associated with unknowingly consuming prohibited substances. Variability between product labeling and actual content represents a defined exposure risk, and third-party certification can reduce the likelihood of inadvertent anti-doping violations.
The BSCG Certified Drug Free program subjects each finished product batch to analytical screening for over 450 substances, including more than 400 WADA-listed agents and 50 prescription, over-the-counter, or illicit drugs not specifically prohibited in sport. The program serves athletes, military service members, first responders, and consumers seeking confirmation that products are free of drugs banned in sport.
Third-party certification uses scientific analysis to verify absence of prohibited agents in finished lots, supporting anti-doping efforts for athletes, military personnel, and other drug-tested professionals. Transparent reporting of substances tested and detection thresholds allows public verification of product integrity.
CJC-1295 and comparable peptide agents present overlapping risks, including regulatory and legal uncertainties. As developmental drugs not approved for human use, these substances frequently enter markets misrepresented as supplements or research chemicals. CJC-1295 is usually found in the form of vials of lyophilized powder designed for inject. Other research chemical products may be distributed as ingestible, injectable, or inhalable chemicals, bypassing clinical trials and regulatory review. Selling research chemicals and unapproved peptides for human consumption or use in any form is not legal at this time in 2026.
Inclusion of any WADA-prohibited peptide carries regulatory, doping, and career consequences. WADA enforces strict liability, and current analytical methods may be able to identify minute concentrations in urine, potentially resulting in anti-doping violations. Military policy applies comparably strict enforcement, including punitive and disciplinary measures for unintentional positive results associated with contaminated supplements.
The minimal quality controls and data gaps regarding peptide safety and efficacy highlight continuing uncertainty. The lack of required studies means consumers may be exposed to products with unknown health risks. Product formulations involving unapproved peptides create reputational and compliance hazards. Verification programs based on robust analytical methods enhance product integrity and consumer protection for stakeholders subject to anti-doping rules.
CJC-1295 is listed in WADA Category S2 as a prohibited peptide hormone and releasing agent due to its potential to facilitate muscle repair and recovery. The WADA List is recognized as the central standard for prohibited substances and informs the policies of athletic organizations, professional leagues, colleges, and military drug testing authorities. Its inclusion on the list impacts both athletic and military personnel due to adopted regulatory frameworks.
Sport and military drug testing typically operates based on strict liability, with comprehensive banned substance screening, and serious outcomes following positive findings, whether due to intentional use or inadvertent supplement exposure. Third-party certification programs that maintain extensive prohibited substance panels serve as a tool for managing risks associated with unauthorized peptides by supporting regulatory and health standards.
WADA Category S2 includes CJC-1295 among prohibited peptide hormones and releasing factors. The prohibition applies in and out of competition. Category S2 is also targeted in U.S. Department of Defense military drug testing.
Sports organizations recognize CJC-1295 under S2 for peptide hormones and releasing agents related to muscle repair and recovery. The WADA Prohibited List guides policy for all Code Signatories, including most professional leagues.
Category S2 peptides are prohibited at all times. Sports and military programs enforce strict liability for any substance detected in athletes or service members, regardless of context.
Blends containing GHRP-6 and CJC-1295 are available on prominent retail platforms, typically as lyophilized powder designed for sub cutaneous injection, reflecting a broader trend of unauthorized peptide sales as research chemicals or supplements while being classified as developmental drugs not approved for human use.
Third-party certification programs screening for WADA-listed drugs apply analytical methodologies to verify product integrity. BSCG covers an industry leading list of more than 450 drugs, include over 400 on the WADA Prohibited List. Using third-party certified products is recommend by groups like the NFL, UFC, and the U.S. Department of Defense Operation Supplement Safety.
FDA advisory committee documents identify risks in nonclinical studies, including reduced hemoglobin, elevated cholesterol, injection site inflammation and necrosis, and DNA damage in pituitary cells. Human safety and efficacy data remain limited for many unapproved peptides like CJC-1295.
YouTube Channel
Oliver Catlin Interview
BSCG BLOG
CJC-1295: Use in Sports and Military Rules Explained
The Catlin Perspective blog widget
THE HISTORY OF BSCG